^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARID1A deletion

    i
    Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
    Entrez ID:
    8289
    Related biomarkers:
    Mutation
    Others
    1m
    ARID1A is a Coactivator of STAT5 that Contributes to CD8+ T Cell Dysfunction and Anti-PD-1 Resistance in Gastric Cancer. (PubMed, Pharmacol Res)
    In addition, targeting STAT5 effectively improved anti-PD-1 efficiency in ARID1A-wild type (WT) GC patients. Taken together, ARID1A is a coactivator of STAT5, function as a chromatin organizer in GC ICIs resistance, and targeting STAT5 is an effective strategy to improve the efficiency of ICIs in GC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • TGFB1 (Transforming Growth Factor Beta 1) • NOX4 (NADPH Oxidase 4) • SMARCD1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 1) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    ARID1A mutation • ARID1A deletion
    11ms
    Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Postoperative adjuvant chemotherapy was given to three patients. AFP-producing adenocarcinoma is a rare subtype of gastric cancer, which can be combined with SWI/SNF complex deletion, and the pathomorphological manifestations are different from the classical SWI/SNF complex deletion of undifferentiated carcinoma with rhabdoid phenotype.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDH1 (Cadherin 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    ARID1A deletion • SMARCA4 deletion • SMARCB1 deletion • CDH1 expression • GPC3 expression • AFP expression
    1year
    SWI/SNF Chromatin Remodeling Complex Orchestrates Sequential Binding of Key Transcription Factors in B Cells and Restricts Aggressive Lymphoma (ASH 2023)
    Remarkably, we further show that FL patients with ARID1A-inactivating mutations display an immature memory B-cell-like state with increased transformation risk to aggressive disease (p=0.0391). These observations offer mechanistic understanding into the emergence of both indolent and aggressive lymphomas in ARID1A-mutant patients through formation of immature memory-like clonal precursors.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • IL6 (Interleukin 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD40 (CD40 Molecule) • IL4 (Interleukin 4) • CD80 (CD80 Molecule)
    |
    ARID1A mutation • ARID1A deletion
    over1year
    ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer. (PubMed, Curr Med Sci)
    Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • EIF4A3 (Eukaryotic Translation Initiation Factor 4A3)
    |
    ARID1A mutation • ARID1A deletion
    |
    cisplatin
    over2years
    ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications. (PubMed, Diagn Pathol)
    We report an ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate, adding to the growing spectrum of SWI/SNF driven undifferentiated sarcoma. Rhabdoid cells can be a helpful morphological clue for promoting molecular and immunohistochemical analyses for deficiency of SWI/SNF subunits, in the diagnostic workup of undifferentiated neoplasms featuring epithelioid or rhabdoid morphology.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • CD34 (CD34 molecule) • VIM (Vimentin)
    |
    ARID1A mutation • ARID1A deletion
    |
    cisplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV
    over3years
    A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. (PubMed, Lab Invest)
    Drug screening demonstrates that both HDAC inhibitor and PARP inhibitor are effective in targeting cells with ARID1A deletion. Together, our data support the potential of hEM3 as a cell line model for studying the pathobiology of endometrium-related diseases and for developing effective precision therapies.
    Preclinical • Journal • PARP Biomarker
    |
    ARID1A (AT-rich interaction domain 1A) • PAX8 (Paired box 8)
    |
    ARID1A deletion
    over3years
    Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. (PubMed, Cancer Discov)
    ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could impact treatment strategies in MBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CDH1 (Cadherin 1) • MDM4 (The mouse double minute 4) • GATA1 (GATA Binding Protein 1)
    |
    TP53 mutation • TMB-H • HER-2 negative • PIK3CA mutation • PTEN mutation • ARID1A mutation • MYC amplification • RB1 mutation • ARID1A deletion • MDM4 amplification • MDM4 mutation
    over4years
    Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. (PubMed, Nat Commun)
    Using a system biology approach and functional studies, we demonstrate that ARID1A-deficiency lead to loss of TGF-β tumor suppressive function and that inactivation of ARID1A/TGF-β axis promotes migration and invasion of PTEN-deleted endometrial tumor cells. These findings provide molecular insights into how ARID1A inactivation accelerates endometrial tumor progression and dissemination, the major causes of cancer mortality.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A)
    |
    PTEN deletion • PTEN mutation • ARID1A mutation • ARID1A deletion